The board of directors lifted Concord Biotech's authorized share capital from ₹11 crore to ₹22 crore, doubling the equity base to 22 crore shares valued at ₹1 each, as per the BSE filing on July 31.
The board also green‑lit a 1:1 bonus share, allocating ₹10.46 crore from the share premium account, which will double the paid‑up equity capital to ₹20.92 crore and raise the share count to 20.92 crore, according to the same filing.
Q1 results showed net profit at ₹58.5 crore, up 32.8% from ₹44.05 crore YoY, while revenue climbed 26.2% to ₹257.4 crore, surpassing the consensus of ₹250 crore set by analysts.
EPS rose to ₹3.10 from ₹2.30, and the EBITDA margin widened to 32% from 30.1%, outpacing the 28% average in the pharma sector.
The shares closed 2.1% higher at ₹1,565, a 17% YTD gain, and saw a 0.5% swing on the announcement of the bonus plan, reflecting investor optimism.
Concord Biotech is slated to release its Q2 earnings on September 30, with guidance of a 10–15% margin improvement, while the board remains pending shareholder approval of the bonus and capital increase.